Key Takeaways
- Soft quarter, timing-driven: Revenue slipped into Q4 because completed work was not shipped within Q3, while front-loaded costs hit the P&L. FY26 guidance of ₹380–400 cr revenue and ₹39–41 cr PAT remains intact.
- Order book is the real story: ₹920+ cr of orders, all pharma/life sciences, to be executed over the next ~18 months, with a major portion falling in FY27.
- Platform model driving bigger wins: Average ticket size has moved from $1.5–5 mn to ~$7 mn as Fabtech now owns process, air, and water capabilities in-house, and win rates improved from 10–12% to 15%.
- Communication reset underway: Management admitted the stock decline was partly self-inflicted by poor communication and has now launched a Twitter account and committed to regular exchange disclosures.
- What to watch next quarter: Whether the deferred Q3 revenue actually lands in Q4, the pace of the European acquisition (likely Q1 FY27), and any decision on switching to percentage-completion revenue recognition.
The Q3 Miss: Timing, Not Demand
- Shipment-based recognition caused the slip: Revenue is booked only when goods ship, not on milestone or progress. A meaningful portion of Q3 execution was completed but not shipped within the period because client sites were not ready to receive, so shipments and inspections moved early into Q4.
- Costs landed, revenue didn't: Q3 absorbed engineering, mobilization, exhibitions, and international business development expenses upfront, while the corresponding revenues will be recognised only in Q4. The quarter reflects the cost; Q4 should reflect the payoff.
- Client accommodation over contract enforcement: Management acknowledged that letters of credit would permit shipment and revenue recognition, but the company sometimes holds shipments to maintain long-term client relationships when buildings are not ready.
- Quarterly fluctuations will persist: Management expects quarter-to-quarter lumpiness to continue for at least the next two years, and urged investors to judge the business on annual guidance, not quarterly prints.
- Revenue recognition transition is 12–16 months away: New contracts are being worded with milestone-linked payments, but the change will only become effective as old shipment-based contracts run off. The company is also evaluating a switch to the percentage-completion method in some geographies, with a decision expected in six months to a year.
Aasif Khan: "Activity happened on the ground, but revenue slipped into quarter four."
Order Book & Pipeline
- ₹920+ cr order book, all life sciences: The entire book is pharmaceutical and life sciences, spanning cell and gene therapy, high-tech medicine, oncology projects in the GCC, and a newly opened animal health vertical in Africa.
- Execution timeline: Projects typically run 9–18 months; the current order book will be executed roughly over the next 18 months, with a major portion in FY27 and 30–40% passing into Q1 or Q2 FY28.
- Order inflow has not slowed: Pipeline visibility remains healthy, with no cancellations or pricing pressures. Management is targeting a ~15% increase in order position by end of FY27 and an order booking ratio of roughly double the revenue growth target.
- Win rate improving: Win rate moved from 10–12% to 15% in the last three months, and the planned European acquisition is expected to push it to 20–25%.
- New verticals emerging: Animal health projects in Africa have opened an entirely new veterinary and animal health manufacturing vertical. The company is also in advanced stages of finalising compounding pharmacy platforms and cell and gene therapy facilities in the GCC.
- Service revenue exploration: One of the first WFI plants being built in Djibouti includes an annual maintenance contract component, and the company is exploring AMCs more broadly, though it does not expect to maintain facilities itself until at least mid-next year.
Aasif Khan: "When we speak about medicinal sovereignty, many assume that this is limited to generate facilities. But in reality, the pipeline ahead is much broader and deeper."
Business Model & Competitive Position
- Platform ownership is the differentiator: Fabtech designs in-house across all dosage formats (sterile injectables, oncology, OSD, high containment, advanced therapies) and manufactures its own critical components: process equipment, air systems, and water systems. This integrated platform enables turnkey start-to-finish project bids that competitors cannot match.
- Ticket sizes have stepped up: Average ticket size increased from $1.5–5 mn to around $7 mn because the company now bids for larger turnkey projects that include external infrastructure, not just equipment supply.
- Ground presence as a moat: Management pushed back on external concerns about execution capability, citing teams on the ground in Kenya, Nigeria, Algeria, Egypt, Saudi, and UAE as a key differentiator in markets perceived as no-go areas by many competitors.
- Export-focused by design: Management declined to split the order book between domestic and export, but stated there is "very, very less of domestic numbers" and that the international farm-emerging market offers such large potential that the company prefers to focus there.
- Design-led, not asset-heavy: The company spends 9–12 months designing the entire process before moving to the technical phase; after design approval, it expects either an advance or LC to kick in before procurement begins.
Aasif Khan: "So there would not be a company like us which has a very strong design platform, in-house design of oral solids to high-tech vaccines or biosimilars or onco. We have a very beautiful platform of manufacturing critical components that go in the project."
Margins, Cash Flow & Working Capital
- Front-loaded costs compress near-term margins: Q3 absorbed marketing and business development expenses (₹8.5–9 cr annually) and other upfront costs without the corresponding revenue. Management noted it has flexibility to trim this spend if needed, as the company is largely seated in its target markets.
- High-growth working capital math: At 30% growth with a 4-month working capital cycle and 10–12% margins, operating cash flow will remain negative during the high-growth phase unless margins become substantially higher, which management considers unrealistic to sustain across all projects.
- Ticket size tailwind for margins: Ticket sizes moving above ₹0.5 cr will naturally help margins through volumes and by leveraging UAE, Saudi, and African supply chains.
- Product IP control as a future lever: Going forward, the company plans to control product IPs, which management believes will make for a more compelling client proposition and potentially support margins.
Strategic Initiatives
- European acquisition in sight: The company is targeting European companies to strengthen conversion rates and positioning in pharmaceutical emerging markets where European firms are expanding. The acquisition is expected in the next six months, likely Q1 FY27, though it could surprise before March 31. Management says it is very diligent on pricing and will not compromise.
- Africa deep-drilling: The company is taking what management called "backhanded steps" (details not disclosed, citing sensitivity) to leverage its UAE and Saudi presence and become domestic in African markets.
- Green energy offering: A tie-up with KP Greens for solar is now being offered as a proposition to clients.
- TSA Process Equipments exit: The company will exit TSA Process Equipments Private Limited (critical water solutions) in the current financial year.
- Communication reset: Management admitted it was "not very communicative" and that the market has not seen a company like Fabtech before. A Twitter account has been launched, and order wins will now be communicated to shareholders via stock exchanges regularly.
Aasif Khan: "Honestly speaking, we were not very communicative, and we have realised that people... The market has not seen anybody and I don't think so the market has seen anybody like us thus far."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY26 revenue and PAT | Revenue ₹380–400 cr, PAT ₹39–41 cr | FY26 (guidance intact) |
| Order book execution | ₹920+ cr order book executed; major portion in FY27, 30–40% spills to Q1/Q2 FY28 | Next ~18 months |
| Order position growth | ~15% increase in order position | By end of FY27 |
| Order booking ratio | Approximately double the revenue growth target | Ongoing |
| European acquisition | Close acquisition of a European target | Next six months; likely Q1 FY27 |
| TSA Process Equipments exit | Exit the subsidiary | Current financial year |
| Revenue recognition method evaluation | Decision on switching to percentage-completion in some geographies | Next six months to a year |
| Milestone-based contract transition | New contract wording becomes effective as old contracts run off | 12–16 months |
| Quarterly fluctuation | Lumpiness expected to persist | At least next two years |
| FY27 growth target | 30% year-on-year growth | FY27 |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹20.3 cr of material lying at port, delayed and to be billed in Q4; softness purely a timing issue |
| FY26 revenue guidance | ₹380–400 cr, reiterated |
| FY26 PAT guidance | ₹39–41 cr, reiterated |
| PAT margin | 9–11%, expected to remain in this range |
| Order book | ₹926 cr as of Jan 31, 2026 |
| Hot lead bank | $455 million |
| Average ticket size | $7 million currently; hot lead bank average $7–10 million |
| Win rate | 15% in last three months, up from 10–12% historically |
| In-house manufactured product share | 30% of supply to a plant, rest from other companies |
| Marketing and business development expense | ₹8.5–9 cr annually |
| Working capital cycle | ~120 days |
| Customer advance | 10–15% advance or full LC; staggered 15%+15% or lump sum 25–30% |
| FY27 growth target | 30% year-on-year |
| Order book execution timeline | 30–40% of ₹900 cr order book to pass into Q1 or Q2 FY28 |
| Other income | ₹7 cr, ~10% of total revenue, primarily interest on FDs |